Skip to navigation Skip to content
  • The Cancer Letter on Facebook
  • The Cancer Letter on Twitter
  • The Cancer Letter on LinkedIn

The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
  • SUBSCRIBE
  • Login
  • SUBSCRIBE
  • Login
The Cancer Letter
Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
Clinical Roundup

A low omega-6, omega-3 rich diet + fish oil may slow prostate cancer growth, UCLA phase III trial finds

January 10, 2025
Vol.51 No.01
Clinical Roundup

UCLA: Advanced imaging uncovers hidden metastases in high-risk prostate cancer cases

January 10, 2025
Vol.51 No.01
Clinical Roundup

Roswell Park team discovers treatment target for neuroendocrine prostate cancer

January 10, 2025
Vol.51 No.01
Clinical Roundup

HIFU demonstrates positive outcomes in management of prostate cancer, study shows

December 13, 2024
Vol.50 No.46
Clinical Roundup

Blood test predicts prognosis for advanced prostate cancer, study finds

December 13, 2024
Vol.50 No.46
In Brief

TD Bank recommits $100K to MUSC Hollings’s SC AMEN program

November 22, 2024
Vol.50 No.44
Clinical Roundup

Mushroom supplement may slow prostate cancer progression, City of Hope study finds

November 22, 2024
Vol.50 No.44
Clinical Roundup

Combination immunotherapy + chemo is safe and effective for advanced small cell cancers in bladder and prostate

November 15, 2024
Vol.50 No.43
A study measures the long-term downside of prostate cancer screening
Trials & Tribulations

A study measures the long-term downside of prostate cancer screening
A paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment

November 08, 2024
Vol.50 No.42
By Otis W. Brawley
Clinical Roundup

Long-term risks from prostate cancer treatment detailed in new report

November 08, 2024
Vol.50 No.42

Posts navigation

Previous1…567…16Next

Trending Stories

  • Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
  • NCI slated to get a $9 million raise as Trump’s budget proposes about 10% cut for NIH
  • Lawsuits brought against Tempus AI raise more questions than answers about DNA privacy in the AI era
  • Trump imposes up to 100% tariff on some brand name pharmaceutical companies
  • FDA’s guidance on MRD in MM goes beyond the ODAC vote—and that’s where it matters most
    Draft guidance consolidates trial design updates for developers
  • Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case

ABOUT
ABOUT
About The Cancer Letter
Accessibility Statement
Our Contributors
Editorial policies
Store
SUBSCRIPTIONS
SUBSCRIPTIONS
Our readers
Pricing
News alerts
About IP login
Job board
CONTACT
CONTACT
Contact us
Submission guidelines
Advertise
Careers
SEE ALSO
Cancer History Project
The Cancer Letter
Copyright © 2026 The Cancer Letter Inc. All rights reserved.
Privacy Policy
Terms & Conditions
FOLLOW US
Instagram
Twitter
LinkedIn
Facebook
Vimeo
Scroll to top
Request Cancellation

Subscription Change

This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level.

OK Cancel

Renew today!

Your subscription has lapsed. Subscribe today to access this content.
SUBSCRIBE NOW

Subscriber content

Log in or subscribe to access The Cancer Letter.
LOGINSUBSCRIBE NOW
SEARCH DATE
SEARCH TEXT
      Cancel
      OK
      Cancel
      OK
      Delete Account
      Are you sure you want to delete your account? This will erase all of your account data from the site. To delete your account enter your password below
      No

      Never miss an issue!

      Get alerts for our award-winning coverage in your inbox.

      Login

       
      Forgot Password?

      Site license subscribers:
      Log in with your IP | Register a sponsored account